Exploiting gene dependency to inform drug development for multiple myeloma.
Date
2022-07-26Author
Went, M
Hoang, PH
Law, PJ
Kaiser, MF
Houlston, RS
Type
Journal Article
Metadata
Show full item recordAbstract
Despite recent advances in therapy, multiple myeloma essentially remains an incurable malignancy. Targeting tumour-specific essential genes, which constitute a druggable dependency, potentially offers a strategy for developing new therapeutic agents to treat MM and overcome drug resistance. To explore this possibility, we analysed DepMap project data identifying 23 MM essential genes and examined the relationship between their expression and patient outcome in three independent series totalling 1503 cases. The expression of TCF3 and FLVCR1 were both significantly associated with progression-free survival. IKBKB is already a drug target in other diseases, offering the prospect of repurposing to treat MM, while PIM2 is currently being investigated as a treatment for the disease. Our analysis supports the rationale of using large-scale genetic perturbation screens to guide the development of new therapeutic agents for MM.
Collections
Subject
Antineoplastic Agents
Drug Development
Humans
Multiple Myeloma
Research team
Cancer Genomics
Language
eng
Date accepted
2022-07-18
License start date
2022-07-26
Citation
Scientific Reports, 2022, 12 (1), pp. 12696 -
Publisher
NATURE PORTFOLIO